Blog
The Tray Comes Back Half-Full: Hospitalized Cancer Patients Miss Up to 1,000 Calories a Day
A new study of 77 hospitalized patients with cancer found they fell short by a median of 867 to 1,012 calories a day — and the blockers were symptoms like appetite loss, dry mouth, and taste changes, not the menu. What the findings mean, and what to ask the care team.
Two Pills, No Chemo: Tumors Shrank in 82% of Pancreatic Cancer Patients in an Early Trial
In an early trial presented at ESMO 2026, two once-daily pills — vopimetostat and daraxonrasib — shrank tumors in 82% of patients with a genetic subtype of advanced pancreatic cancer, most on their third line of therapy. What the results mean, the side effects, and the Phase 3 test that comes next.
Chemotherapy's Burden Rivals the Cancer Itself: 119 Patients Speak Out
A survey of 119 U.S. endometrial cancer patients, presented at ESMO 2026, found 70% felt the burden of chemotherapy was almost as much as the burden of the cancer itself — fatigue 93%, nausea 82%, muscle cramps 76%, and 59% who felt unprepared. Here is what patients reported, in plain language, and how to prepare.
Keytruda Gets Full Approval for TMB-High Cancers — But the Cutoff Just Moved From 10 to 13
On October 16, 2026, the FDA converted Keytruda's approval for TMB-high solid tumors from accelerated to full — and raised the cutoff from 10 to 13 mutations per megabase. Here is what tumor mutational burden means, why the line moved, and what it means if your score was 10, 11, or 12.
FDA Grants Accelerated Approval to Jemperli for Rectal Cancer: Immunotherapy Alone, Without Chemo, Radiation, or Surgery
On October 19, 2026, the FDA granted accelerated approval to Jemperli (dostarlimab) — immunotherapy alone — for adults with stage II or III MSI-H/dMMR rectal cancer. In the AZUR-1 study, nearly half of patients had no detectable cancer a full year after treatment, and many avoided chemotherapy, radiation, and surgery. Here is what the news means, in plain language.
Your Gut Bacteria May Predict Chemo Side Effects: What a Landmark Mayo Clinic Study Found
A Mayo Clinic study of 1,364 cancer patients, published in the journal Cell, found that gut bacteria are linked to five cancer groups, to survival, and even to who develops diarrhea from the chemotherapy drug 5-FU. Here is what the research means for patients and caregivers, in plain language.
FDA Approves Immunotherapy Plus Chemotherapy for Stage III Colon Cancer: What Patients Need to Know
On October 8, 2026, the FDA approved atezolizumab (Tecentriq) plus chemotherapy after surgery for stage III colon cancer with deficient mismatch repair (dMMR). In the ATOMIC trial, the combination cut the risk of the cancer coming back or death by 50%. Here is what the news means for patients and caregivers, in plain language.
Cancer Cachexia Explained: New Research Shows Weight Loss Can Start Earlier Than Expected
A major new Nature Medicine study found that nearly half of cancer patients experienced significant weight-loss episodes linked to cachexia. Learn what cancer cachexia is, why it can begin early, and what the new findings mean for patients and caregivers.
Depression and Cancer: Why Mental Health Is Part of Cancer Care
Depression during cancer treatment may affect more than quality of life. New research links depression with poorer cancer outcomes and highlights why mental health support should be part of supportive cancer care.
HuMOLYTE Presents Chemotherapy Support Research at the 2026 Microbiome Forum
HuMOLYTE presented its latest research on chemotherapy-related mucositis at the 2026 Microbiome Forum in San Diego. Watch Dr. Sourabh Kharait’s presentation and explore our poster featuring preclinical findings and encouraging results from an initial 32-patient study.
October is Breast & Liver Cancer Awareness Month
October shines a light on breast cancer, metastatic breast cancer, and liver cancer. For patients and caregivers, it’s a time to focus on early detection, support, and advocacy.
Cancer Treatment Is More Than Fighting the Tumor: Why Supportive Care Matters
Cancer treatment is about more than shrinking a tumor. Supportive care helps patients manage pain, nausea, diarrhea, dehydration, mouth sores, nutrition problems, fatigue, frailty, and other side effects that can make treatment harder to tolerate.
WHO Oral Mucositis Grading Scale: Understanding Grades 0–4
The WHO oral mucositis grading scale classifies mouth sores from Grade 0 to Grade 4 based on redness, ulceration, and the ability to eat and drink. Learn what each grade means, how the scale is used during cancer treatment, and how it compares with OMAS and CTCAE.
How HuMOLYTE Supported One Family Through Chemotherapy and Recovery
One family turned to HuMOLYTE during two difficult health journeys: chemotherapy for stage 4 lymphoma and recovery after prostate surgery. Hear their experience with hydration, gut health, and treatment support.
2′-FL & Chemotherapy-Induced Mucositis: HuMOLYTE Study
Chemotherapy can damage the protective lining of the mouth and gastrointestinal tract, contributing to mucositis, diarrhea, dehydration, and electrolyte loss. A peer-reviewed 2026 study investigated whether HuMOLYTE—a medical food containing 2′-fucosyllactose (2′-FL), magnesium, and electrolytes—could help support the mucosal barrier during chemotherapy. Here’s what researchers found in preclinical animal and laboratory models.
Cancer Drug Shortages Are Disrupting Treatment: What Patients Should Know
Cancer drug shortages are affecting major cancer centers across the U.S., including shortages of ifosfamide, carboplatin, and cisplatin. Learn why these shortages happen, how they can disrupt treatment, and what patients should ask their oncology team.
HuMOLYTE Founder Dr. Sourabh Kharait to Present Research at Microbiome 2026
HuMOLYTE founder Dr. Sourabh Kharait will present the company’s preclinical and early clinical research on chemotherapy-induced mucositis at Microbiome 2026, highlighting the potential role of 2′-FL HMO, mucosal barrier support, and gut health during cancer treatment.
Could Psilocybin Prevent Chemotherapy-Induced Neuropathy?
New preclinical research from MD Anderson suggests psilocybin may help prevent chemotherapy-induced peripheral neuropathy by protecting nerve cells. Here’s what the study found, how it may work, and why human trials are still needed.
What Is the Oral Mucositis Assessment Scale (OMAS)? How Researchers Measure Mouth Sores During Cancer Treatment
The Oral Mucositis Assessment Scale (OMAS) gives researchers an objective way to measure mouth sores caused by chemotherapy and radiation therapy. Learn how OMAS scores redness and ulceration, how it differs from WHO mucositis grades, and why standardized assessment matters in cancer research.
Cancer Awareness in September: A Month of Many Voices
September is one of the most powerful months for cancer awareness, honoring childhood, ovarian, prostate, thyroid, blood, and gynecologic cancers. Each ribbon tells a story, each campaign sparks conversation, and together they create a movement for education, early detection, and support.